



(51) International Patent Classification:

A61P 3/08 (2006.01) *C07D 413/04* (2006.01)
A61P 19/08 (2006.01) *C07D 413/14* (2006.01)
A61P 25/28 (2006.01)

(21) International Application Number:

PCT/IB2023/062016

(22) International Filing Date:

29 November 2023 (29.11.2023)

(25) Filing Language:

English

(26) Publication Language:

English


(30) Priority Data:

63/385,598 30 November 2022 (30.11.2022) US

(71) Applicant: **TAKEDA PHARMACEUTICAL COMPANY LIMITED** [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka 541-0045 (JP).(72) Inventors: **KINA, Asato**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa 251-0012 (JP). **IKEDA, Zenichi**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa 251-0012 (JP). **KONO, Mitsunori**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa 251-0012 (JP). **OGURO, Yuya**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa 251-0012 (JP). **KUBO, Osamu**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa 251-0012 (JP). **YAMASHITA, Toru**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa 251-0012 (JP).

TAKAMI, Kazuaki; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa 251-0012 (JP). **YUKAWA, Takafumi**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa 251-0012 (JP). **SETO, Masaki**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa 251-0012 (JP). **KAMATA, Makoto**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa 251-0012 (JP). **SATO, Kenjiro**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa 251-0012 (JP). **MURAKAMI, Masataka**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa 251-0012 (JP). **SASAKI, Yusuke**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa 251-0012 (JP). **REYNOLDS, Matthew Thomas**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa 251-0012 (JP). **NAKAMURA, Minoru**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa 251-0012 (JP). **KAMEI, Taku**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa 251-0012 (JP). **KAKEI, Hiroyuki**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa 251-0012 (JP). **YAMAGUCHI, Fumie**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa 251-0012 (JP). **OHASHI, Tomohiro**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi,

(54) Title: HETEROCYCLIC COMPOUND AND USE THEREOF



(I)

(57) **Abstract:** The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. Provided is a compound of formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

[Continued on next page]

Kanagawa 251-0012 (JP). **KOJIMA, Takuto**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa 251-0012 (JP). **KAKEGAWA, Keiko**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa 251-0012 (JP). **PÜNNER, Florian**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa 251-0012 (JP). **NAKAMURA, Shinji**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa 251-0012 (JP). **MORISHITA, Nao**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa 251-0012 (JP). **HIDAKA, Tadashi**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa 251-0012 (JP). **TAKASHIMA, Sachie**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa 251-0012 (JP). **TANIGUCHI, Takahiko**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa 251-0012 (JP).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))